7 results on '"van Herpen, Carla M. L."'
Search Results
2. Methylated Cell-Free DNA Sequencing (MeD-seq) of LpnPI Digested Fragments to Identify Early Progression in Metastatic Renal Cell Carcinoma Patients on Watchful Waiting.
- Author
-
Bos, Manouk K., Verhoeff, Sarah R., Oosting, Sjoukje F., Menke-van der Houven van Oordt, Willemien C., Boers, Ruben G., Boers, Joachim B., Gribnau, Joost, Martens, John W. M., Sleijfer, Stefan, van Herpen, Carla M. L., and Wilting, Saskia M.
- Subjects
RENAL cell carcinoma ,DISEASE progression ,SEQUENCE analysis ,METASTASIS ,HEALTH outcome assessment ,DNA methylation ,RISK assessment ,COMPARATIVE studies ,DESCRIPTIVE statistics ,RESEARCH funding ,TUMOR markers ,EXTRACELLULAR space ,PROGRESSION-free survival ,NUCLEIC acids ,EARLY diagnosis ,PROPORTIONAL hazards models ,EVALUATION - Abstract
Simple Summary: A subset of patients with an intermediate risk for renal cell carcinoma have an indolent disease course. For these patients, the initiation of treatment for metastatic disease can be safely delayed by entering a watchful waiting period. At present, we are not able to identify those patients with indolent disease and the minor group of patients with rapidly progressive disease requiring earlier initiation of systemic treatment. In this study, we investigate whether cell-free DNA (cfDNA) can be used as a blood-based biomarker to identify those patients with rapid progression. Methylated cfDNA profiles were used as a proxy for tumor load in blood. cfDNA methylation patterns were associated with the time to radiological progression, but not with the watchful waiting time. The results of this study do not provide definite proof that cfDNA methylation patterns are associated with WW time. According to the current guidelines, watchful waiting (WW) is a feasible option for patients with good or intermediate prognosis renal-cell carcinoma (RCC). However, some patients rapidly progress during WW, requiring the initiation of treatment. Here, we explore whether we can identify those patients using circulating cell-free DNA (cfDNA) methylation. We first defined a panel of RCC-specific circulating methylation markers by intersecting differentially methylated regions from a publicly available dataset with known RCC methylation markers from the literature. The resulting RCC-specific methylation marker panel of 22 markers was subsequently evaluated for an association with rapid progression by methylated DNA sequencing (MeD-seq) in serum from 10 HBDs and 34 RCC patients with a good or intermediate prognosis starting WW in the IMPACT-RCC study. Patients with an elevated RCC-specific methylation score compared to HBDs had a shorter progression-free survival (PFS, p = 0.018), but not a shorter WW-time (p = 0.15). Cox proportional hazards regression showed that only the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria were significantly associated with WW time (HR 2.01, p = 0.01), whereas only our RCC-specific methylation score (HR 4.45, p = 0.02) was significantly associated with PFS. The results of this study suggest that cfDNA methylation is predictive of PFS but not WW. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Exposure‐toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer.
- Author
-
Krens, Stefanie D., van Boxtel, Wim, Uijen, Maike J. M., Jansman, Frank G. A., Desar, Ingrid M. E., Mulder, Sasja F., van Herpen, Carla M. L., and van Erp, Nielka P.
- Subjects
SALIVARY gland cancer ,RENAL cancer ,PROTEIN-tyrosine kinase inhibitors ,CELLULAR signal transduction ,RENAL cell carcinoma ,GALACTOMANNANS ,KINASE inhibitors - Abstract
Cabozantinib is registered in fixed 60 mg dose. However, 46% to 62% of patients in the registration studies needed a dose reduction due to toxicity. Improved clinical efficacy has been observed in renal cell carcinoma patients (RCC) with a cabozantinib exposure greater than 750 μg/L. In our study we explored the cabozantinib exposure in patients with different tumour types. We included RCC patients from routine care and salivary gland carcinoma (SGC) patients from a phase II study with ≥1 measured Cmin at steady‐state. The geometric mean (GM) Cmin at the starting dose, at 40 mg and at best tolerated dose (BTD) were compared between both tumour types. Forty‐seven patients were included. All SGC patients (n = 22) started with 60 mg, while 52% of RCC patients started with 40 mg. GM Cmin at the start dose was 1456 μg/L (95% CI: 1185‐1789) vs 682 μg/L (95% CI: 572‐812) (P <.001) for SGC and RCC patients, respectively. When dose‐normalised to 40 mg, SGC patients had a significantly higher cabozantinib exposure compared to RCC patients (Cmin 971 μg/L [95% CI: 790‐1193] vs 669 μg/L [95% CI: 568‐788]) (P =.005). Dose reductions due to toxicity were needed in 91% and 60% of SGC and RCC patients, respectively. Median BTD was between 20 to 30 mg for SGC and 40 mg for RCC patients. GM Cmin at BTD were comparable between the SGC and the RCC group, 694 μg/L (95% CI: 584‐824) vs 583 μg/L (95% CI: 496‐671) (P =.1). The observed cabozantinib exposure at BTD of approximately 600 μg/L is below the previously proposed target. Surprisingly, a comparable exposure at BTD was reached at different dosages of cabozantinib for SGC patients compared to RCC patients Further research is warranted to identify the optimal exposure and starting dose to balance efficacy and toxicity. What's new? Cabozantinib, a potent tyrosine kinase inhibitor that targets multiple signaling pathways, is approved for use against advanced renal cell carcinoma (RCC). Variations in cabozantinib clearance, however, warrant further investigation. Here, the authors evaluated cabozantinib exposure in RCC patients and in patients with salivary gland cancer (SGC). SGC patients were found to have significantly higher cabozantinib exposure compared to RCC patients following a 40 mg dose. However, the best‐tolerated cabozantinib exposure was equivalent (~600 μg/L) for both tumor types and was substantially below the previously proposed target. The findings offer insight on exposure, dose, and the balance between efficacy and toxicity for cabozantinib. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma.
- Author
-
Verhoeff, Sarah R., van Es, Suzanne C., Boon, Eline, van Helden, Erik, Angus, Lindsay, Elias, Sjoerd G., Oosting, Sjoukje F., Aarntzen, Erik H., Brouwers, Adrienne H., Kwee, Thomas C., Heskamp, Sandra, Hoekstra, Otto S., Verheul, Henk, van der Veldt, Astrid A. M., de Vries, Elisabeth G. E., Boerman, Otto C., van der Graaf, Winette T. A., Oyen, Wim J. G., and van Herpen, Carla M. L.
- Subjects
CONTRAST-enhanced ultrasound ,RENAL cell carcinoma ,INTERMEDIATE goods ,WATCHFUL waiting ,IMAGE analysis ,LYMPH nodes - Abstract
Purpose: The main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced CT, [
89 Zr]Zr-DFO-girentuximab-PET/CT and [18 F]FDG-PET/CT in detecting ccRCC lesions in patients with a good or intermediate prognosis metastatic clear cell renal cell carcinoma (mccRCC) according to the International Metastatic Database Consortium (IMDC) risk model. Methods: Between February 2015 and March 2018, 42 newly diagnosed mccRCC patients with good or intermediate prognosis, eligible for watchful waiting, were included. Patients underwent CT, [89 Zr]Zr-DFO-girentuximab-PET/CT and [18 F]FDG-PET/CT at baseline. Scans were independently reviewed and lesions of ≥10 mm and lymph nodes of ≥15 mm at CT were analyzed. For lesions with [89 Zr]Zr-DFO-girentuximab or [18 F]FDG-uptake visually exceeding background uptake, maximum standardized uptake values (SUVmax ) were measured. Results: A total of 449 lesions were detected by ≥1 modality (median per patient: 7; ICR 4.25–12.75) of which 42% were in lung, 22% in lymph nodes and 10% in bone. Combined [89 Zr]Zr-DFO-girentuximab-PET/CT and CT detected more lesions than CT alone: 91% (95%CI: 87–94) versus 56% (95%CI: 50–62, p = 0.001), respectively, and more than CT and [18 F]FDG-PET/CT combined (84% (95%CI:79–88, p < 0.005). Both PET/CTs detected more bone and soft tissue lesions compared to CT alone. Conclusions: The addition of [89 Zr]Zr-DFO-girentuximab-PET/CT and [18 F]FDG-PET/CT to CT increases lesion detection compared to CT alone in newly diagnosed good and intermediate prognosis mccRCC patients eligible for watchful waiting. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
5. Boosting axitinib exposure with a CYP3A4 inhibitor, making axitinib treatment personal.
- Author
-
Lubberman, Floor J. E., van Erp, Nielka P., ter Heine, Rob, and van Herpen, Carla M. L.
- Subjects
DRUG therapy ,METASTASIS ,RENAL cell carcinoma ,PROTEIN-tyrosine kinase inhibitors ,TREATMENT effectiveness ,THERAPEUTICS - Published
- 2017
- Full Text
- View/download PDF
6. A Phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).
- Author
-
Grünwald, Viktor, Desar, Ingrid M. E., Haanen, John, Fiedler, Walter, Mouritzen, Ulrik, Olsen, M. W. Brændholt, and van Herpen, Carla M. L.
- Subjects
ANALYSIS of variance ,ANTINEOPLASTIC agents ,COMBINATION drug therapy ,CLINICAL trials ,COMPUTER software ,DRUG toxicity ,IMMUNOTHERAPY ,INTERLEUKIN-2 ,METASTASIS ,HEALTH outcome assessment ,PHARMACEUTICAL arithmetic ,RENAL cell carcinoma ,RESEARCH funding ,TOXICITY testing ,TRANSFERASES ,DATA analysis ,TREATMENT effectiveness ,DRUG dosage - Abstract
Background. Sunitinib induces partial responses in 47% of patients with metastatic renal cell carcinoma (mRCC). However, the achievement of complete responses remains scarce and all patients will eventually develop progressive disease. Recombinant interleukin-21 (rIL-21) is a novel cytokine, which is believed to deliver sustained cellular anti-tumor response and the combination of both agents may work synergistically. Material and method. From July 2007 to July 2008 in this phase I trial nine therapy-naive patients with metastatic RCC in five European centers were enrolled. Patients with either good or intermediate risk according to Memorial Sloan-Kettering Cancer Center (MSKCC) were eligible without restrictions to histology subtype nor measurable disease. Patients were treated with increasing doses of rIL-21 administered subcutaneously (s.c.) in combination with sunitinib 50 mg once daily (OD) orally at the '4 weeks on/2 weeks off' schedule. Dose-escalation was applied by a conventional '3+3 design'. Planned dose levels (DL) for rIL-21 were 3, 10, 30 and 100 μg/kg s.c. The primary endpoint was to determine the maximum tolerated dose (MTD) and recommended dose (RD). Secondary objectives included pharmacokinetics of sunitinib and rIL-21, and the induction of rIL-21 antibodies. Results. At 10 μg/kg two dose-limiting toxicities (DLT) occurred in four patients, consisting of grade 4 neutropenia and grade 3 thrombocytopenia. The MTD was 3 μg/kg rIL-21 combined with sunitinib 50 mg OD at the '4 weeks on/2 weeks off' schedule. Frequent occurring adverse events were injection site reaction, stomatitis, fatigue and dysgeusia. Conclusions. The combination of sunitinib 50 mg at the '4 weeks on/2 weeks off' schedule and 10 μg/kg IL-21 was not tolerated due to hematological DLTs. The dose level of 3 μg/kg rIL-21 was considered too low to be therapeutically relevant for further evaluation and therefore the study was discontinued. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
7. The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
- Author
-
DESAR, INGRID M. E., MULDER, SASJA F., STILLEBROER, ALEXANDER B., VAN SPRONSEN, DICK-JOHAN, VAN DER GRAAF, WINETTE T. A., MULDERS, PETER F. A., and VAN HERPEN, CARLA M. L.
- Subjects
LETTERS to the editor ,RENAL cell carcinoma - Abstract
A letter to the editor is presented describing three patients with metastatic renal cell carcinoma (mRCC) who experienced unexpectedly rapid progression and tumourrelated complaints after discontinuation of oral angiogenesis inhibitors.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.